GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » Debt-to-Equity

UroGen Pharma (UroGen Pharma) Debt-to-Equity : -1.52 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma Debt-to-Equity?

UroGen Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. UroGen Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $99.40 Mil. UroGen Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-65.21 Mil. UroGen Pharma's debt to equity for the quarter that ended in Dec. 2023 was -1.52.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for UroGen Pharma's Debt-to-Equity or its related term are showing as below:

URGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.52   Med: 0.01   Max: 0.05
Current: -1.52

During the past 9 years, the highest Debt-to-Equity Ratio of UroGen Pharma was 0.05. The lowest was -1.52. And the median was 0.01.

URGN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs URGN: -1.52

UroGen Pharma Debt-to-Equity Historical Data

The historical data trend for UroGen Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Debt-to-Equity Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.01 0.02 0.05 -1.11 -1.52

UroGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.11 -0.85 -0.72 -2.37 -1.52

Competitive Comparison of UroGen Pharma's Debt-to-Equity

For the Biotechnology subindustry, UroGen Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Debt-to-Equity falls into.



UroGen Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

UroGen Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

UroGen Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UroGen Pharma  (NAS:URGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


UroGen Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


UroGen Pharma (UroGen Pharma) Business Description

Traded in Other Exchanges
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Executives
Jason Drew Smith officer: General Counsel C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Mark Schoenberg officer: Chief Medical Officer C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Daniel George Wildman director 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim officer: Chief Financial Officer C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett officer: Chief Executive Officer C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix officer: COO C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden director C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur director, officer: Chief Executive Officer 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102